Based on NIH | In patients with endometrial cancer, what should a shortness of breath patient checklist include to screen for pulmonary embolism, pleural effusion, infection, anemia, and treatment-related cardiopulmonary toxicity?

A practical, safety‑focused shortness‑of‑breath checklist for people with endometrial cancer should quickly flag life‑threats (like pulmonary embolism) while prompting targeted history, exam, and first‑line tests for common causes such as blood clots, pleural effusion, infection, anemia, and treatment‑related heart–lung toxicity. The items below are organized for rapid triage and stepwise evaluation you can adapt into clinic or infusion‑center workflows. ^{[1] [2]}

---

Red‑flag triage (immediate action)

• Chest pain worse with deep breaths or cough, sudden trouble breathing, coughing up blood, fast or irregular heartbeat. These may suggest a pulmonary embolism and warrant emergency evaluation. ^{[1] [2]}
• New or rapidly worsening shortness of breath during or after cancer treatment, especially with fever or new cough. Consider infection or drug‑related lung inflammation; escalate care promptly. ^[3]
• Shortness of breath with leg swelling or pain, confusion, dizziness, or fainting. This may indicate clot propagation, cardiotoxicity, or severe anemia and requires urgent assessment. ^{[1] [4]}

---

Targeted history

• Onset and time course: sudden vs gradual; relation to exertion or rest. Sudden onset is more concerning for pulmonary embolism, while gradual may suggest anemia, pleural effusion, or treatment toxicity. ^{[1] [5] [3]}
• Associated symptoms:
  • Pleuritic chest pain, hemoptysis, palpitations. PE screening focus. ^{[1] [2]}
  • Fever, chills, purulent sputum, new or worsening cough. Infection/pneumonia consideration. ^[3]
  • Orthopnea, paroxysmal nocturnal dyspnea, ankle swelling. Possible heart failure or cardiotoxicity. ^[4]
  • Fatigue, lightheadedness, pallor, reduced exercise tolerance. Suggestive of anemia. ^[5]
  • Weight gain, early satiety, abdominal distension; known effusions. Raises suspicion for pleural effusion. ^[6]
• Cancer treatment exposures: chemotherapy (e.g., anthracyclines), immunotherapy, targeted therapy, and any chest radiation. These can cause myocarditis, reduced heart function, arrhythmias, or drug‑induced pneumonitis. ^{[4] [3]}
• VTE risk factors: recent surgery or immobility, prior DVT/PE, central venous catheter, hormonal therapy, long travel. Cancer and its treatments elevate clot risk. ^{[7] [8]}
• Exacerbating/relieving factors and baseline function. Clarifies severity and trend. ^[9]

---

Focused physical exam

• Vital signs: heart rate, blood pressure, respiratory rate, oxygen saturation, temperature. Tachycardia, hypoxia, fever help stratify PE, infection, and decompensation risk. ^{[1] [3]}
• Cardiorespiratory:
  • Lungs: decreased breath sounds or dullness to percussion (effusion), crackles (edema or infection), wheeze, signs of pneumonitis. These guide imaging next steps. ^{[6] [3]}
  • Heart: new murmurs, gallop rhythm, irregular pulse, jugular venous distention, peripheral edema. Supports cardiotoxicity or heart failure. ^[4]
• Extremities: unilateral leg swelling, calf tenderness, redness, warmth. Supports DVT as a source for PE. ^[1]
• General: pallor (anemia), altered mental status (hypoxia or severe anemia). Adds urgency and direction. ^[5]

---

First‑line tests

• Pulse oximetry ± arterial/venous blood gas if hypoxia is significant. Quantifies severity of respiratory compromise. ^[10]
• CBC with differential. Screens for anemia and infection (leukocytosis). ^[5]
• Basic metabolic panel and liver tests. Establishes organ status and treatment tolerance. ^[5]
• ECG and cardiac troponin/BNP if chest discomfort, dyspnea, or exposure to cardiotoxic agents. Evaluates myocarditis, ischemia, or heart failure related to therapy. ^[4]
• Chest X‑ray. Rapidly detects pneumonia patterns, pleural effusion, or alternative diagnoses and is recommended in gynecologic cancer evaluation. ^{[6] [11]}

---

Imaging and advanced diagnostics (as indicated)

• CT pulmonary angiography for suspected PE. Definitive imaging when PE red flags or high clinical suspicion are present. ^{[1] [2]}
• Lower‑extremity venous duplex ultrasound if leg findings or when CTPA is contraindicated. Identifies DVT as PE source. ^[1]
• Thoracic ultrasound and diagnostic thoracentesis for pleural effusion with significant dyspnea. Relieves symptoms and analyzes fluid for infection or malignancy. ^{[6] [5]}
• Transthoracic echocardiogram for heart failure signs, cardiotoxic drug exposure, or unexplained dyspnea. Assesses ejection fraction, pericardial disease, and pulmonary pressures. ^[4]
• High‑resolution CT or CT chest if persistent dyspnea with normal X‑ray and suspicion for drug‑induced pneumonitis or interstitial lung disease. Helps define treatment‑related pulmonary toxicity. ^[3]

---

Cause‑focused decision nodes

• Suspected/confirmed pulmonary embolism: Initiate emergency pathway for anticoagulation and hospital evaluation; large PE can be fatal without prompt treatment. ^{[2] [1]}
• Pleural effusion causing dyspnea: Drainage improves breathing and fluid analysis guides treatment of infection vs malignant effusion. ^{[6] [5]}
• Infection/pneumonia: Start timely antibiotics and supportive care, especially in immunocompromised or post‑chemotherapy settings. ^[3]
• Anemia: Investigate cause and consider transfusion or iron/erythropoiesis‑stimulating strategies as appropriate to severity and context. ^[5]
• Cardiotoxicity from therapy: Coordinate with cardio‑oncology for biomarker tracking, imaging, and potential modification or holding of the cancer regimen. ^[4]

---

Treatment‑related toxicity watchlist

• Anthracyclines, HER2‑targeted agents, VEGF inhibitors, and certain immunotherapies can lead to reduced heart function, myocarditis, arrhythmias, or hypertension‑related complications. Screen proactively when these drugs are used or within months afterward. ^{[4] [12]}
• Multiple anticancer agents and supportive drugs are linked to interstitial lung disease, pneumonitis, and effusions. New or worsening dyspnea, cough, fever, or hypoxia during therapy should prompt evaluation for drug‑induced lung injury. ^[3]

---

Infusion‑center and clinic safety prompts

• During active systemic therapy: if shortness of breath, chest pain, rapid heartbeat, new cough, or fever occur, notify the oncology team immediately and follow emergency protocols. These symptoms during treatment can signal serious lung or heart complications. ^[13]
• After chemotherapy cycles: any new leg swelling, chest pain, or shortness of breath should trigger same‑day medical assessment or emergency care, given the elevated clot risk with cancer and treatment. Early recognition reduces mortality. ^{[1] [2]}

---

Printable checklist template

Use the following structured items for every shortness‑of‑breath presentation in endometrial cancer:

• Onset/course: sudden vs gradual; exertional vs rest. ^[9]
• Red flags: pleuritic chest pain, hemoptysis, severe dyspnea, tachycardia/arrhythmia, syncope, leg swelling/pain, fever. ^{[1] [2] [3]}
• Treatment exposures: list current/recent chemo, immunotherapy, targeted agents, radiation. ^{[4] [3]}
• Vitals: HR, BP, RR, SpO2, temperature. ^[3]
• Exam: lungs (effusion signs, crackles), heart (JVD, edema, rhythm), legs (DVT signs), pallor. ^{[6] [4] [1] [5]}
• Labs: CBC with differential, BMP/LFTs, troponin/BNP if indicated. ^{[5] [4]}
• Imaging: chest X‑ray first; then CTPA for PE suspicion; leg ultrasound if DVT suspected; echo if cardiotoxicity signs; chest CT/HRCT if pneumonitis suspected; thoracic ultrasound ± thoracentesis if effusion. ^{[6] [1] [4] [3] [5]}
• Disposition: emergency pathway for suspected PE or severe hypoxia; admit if unstable or high‑risk. Document response and follow‑up plan. ^{[1] [2]}

---

Why this matters

Shortness of breath in cancer is common and multifactorial, so rapid identification of underlying causes is essential for effective treatment and comfort. A structured checklist improves speed and accuracy of diagnosis, which is critical because PE is a leading non‑cancer cause of death in people with cancer, and timely management of effusion, infection, anemia, and cardiopulmonary toxicities markedly improves outcomes. ^{[9] [2] [6] [4]}